Cargando…
Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19
The recent pandemic of COVID-19 caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an extraordinary challenge to identify effective drugs for prevention and treatment. The pathogenesis implicate acute respiratory disorder (ARD) which is attributed to significan...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833560/ https://www.ncbi.nlm.nih.gov/pubmed/33259924 http://dx.doi.org/10.1016/j.pupt.2020.101978 |